Frequency of OSM in Patients with Relapsing-Remmiting Multiple Sclerosis
Mohammadreza Shahmohammadi1, Reza Jalil Khoshnod1 , Nima Mohseni Kabir1 and Peyman Karimi Goudarzi2*Department of Neurosurgery , Shahid Beheshti University of Medical Sciences , Tehran , Iran Department of Neurosurgery , AJA University of Medical Sciences , Tehran , Iran Corresponding Author Email: pedram_kg@yahoo.com
Abstract: Multiple Sclerosis (MS) is a chronic disease with an unknown cause that results in inflammation and destruction of Myelin in central nervous system (CNS). The final result is disruption of nervous system functions. This disorder commences at the age of 10 to 60 and her frequency among women is two to three times more than what is recorded among men. As we move further from the equator, the prevalence of this disease increases, so does its variation in various races. The commonest type of MS is the Relapsing-Remmiting multiple Sclerosis. Oncostatin M (OSM) is a Cytokine in Interleukin 6 family (IL-6). OSM is secreted in patients with multiple Sclerosis. OSM improves E2 expression of prostaglandin and cyclooxygenases-2 in astrocytes. This action is of great significance in the efficiency of CNS endothelial cells and creation of blood brain barrier (BBB). The present study seeks to study the frequency distribution of Oncostatin M in the patients suffering from Relapsing-Remmiting multiple Sclerosis and healthy control individuals. The present research has been conducted using a case-control method. 83 patients who had resorted to a private hospital in Tehran due to having the clinical symptoms of multiple Sclerosis whose disease was confirmed by the neurologists based on Mc Donald criteria were randomly selected for this research. All the above-mentioned patients entered the study on the condition of meeting the acceptance criteria. The population was divided into two groups, namely case (patients with MS) and control (healthy people without chronic inflammatory or neurogenetic disease). 5 cc blood was obtained on anticoagulant EDTA and preserved in a temperature of -80 for the later phases of the research. Finally, ELISA test was conducted utilizing EastBiopharm Company protocols and the data resulting from the analysis of micro-plate reader device was collected for statistical analysis phase. The raw data was then entered in SPSS version 19 and independent t-test and Spearman Correlation tests were used to analyze the data. The significant level of the possible value was set to (P-Value < 0.05). Studying the serum level of OSM in both groups (patients and healthy individuals) is indicative of the fact that although the OSM serum density in patients (634.68 658.43(pg/ml)) was much less than the level observed in healthy cases (860.57 891/16(pg/ml)), this difference was by no means statistically significant (P-Value > 0.05). The results of studying the correlation between the expanded disability status scale (EDSS) and the Oncostatin M density level in the group of the patients indicated no statistically significant relationship between the parameters in the group mentioned (P-Value = 0.471). MS plays no major role in changing OSM serum level and EDSS is a variable independent from OSM serum density parameter.
Keywords: Multiple Sclerosis; CNS; RRMS; OSM; Oncostatin M Back to TOC